AGI-134 is a synthetic molecule that by intratumoral injection triggers a systemic anti-tumor response.
AGI-134 is indicated to treat an unresectable solid tumor which is a tumor that cannot be removed completely through surgery, radiation therapy, drug treatment or any combination of them.
AGI-134 is administered via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles
AGI-134 Clinical Trial
Clinical Trial NCT03593226: Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour (Recruiting)
- This study will evaluate the safety, tolerability, and efficacy of AGI-134 given alone and in combination with pembrolizumab in treating patients with unresectable metastatic solid tumors.
- This study is divided into 2 parts:
- Part 1 will assess on a small group of subjects the safety and tolerability of increasing doses of AGI-134 injected intra-tumourally (IT) and will determine the maximum AGI-134 dose that can be tolerated.
- Part 2 will assess the safety, tolerability and clinical effect of the dose selected in part 1 in a group of subjects who will receive AGI-134 alone injected intra-tumourally and in a group of subjects who will receive AGI-134 in combination with Pembrolizumab.